Match!
Katrina M. Moore
UCL Institute of Neurology
PsychiatryPsychologyC9orf72Frontotemporal dementiaDiseaseMedicine
9Publications
1H-index
3Citations
What is this?
Publications 14
Newest
#1Katrina M. Moore (UCL Institute of Neurology)H-Index: 1
#2Rhian S. Convery (UCL Institute of Neurology)H-Index: 2
Last. John C. van Swieten (EUR: Erasmus University Rotterdam)H-Index: 53
view all 38 authors...
AbstractImpaired semantic knowledge is a characteristic feature of some forms of frontotemporal dementia (FTD), particularly the sporadic disorder semantic dementia. Less is known about semantic co...
Source
#1Katrina M. Moore (UCL: University College London)H-Index: 1
#2Jennifer M. Nicholas (Lond: University of London)H-Index: 20
Last. Daniel H. GeschwindH-Index: 129
view all 171 authors...
Summary Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. Methods In this international, retrospective cohort study, we col...
2 CitationsSource
#1Carolin Heller (UCL: University College London)
#1Carolin Heller (UCL: University College London)H-Index: 3
Last. Jonathan D. RohrerH-Index: 50
view all 38 authors...
Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker. Methods Plasma GFAP and neurofilament light chain (NfL) concentration were measured in 469 individuals enrolled in the Genetic FTD Initiative: 114 C9orf72 expansion carriers (74 presymptomatic, 40 symptomatic), 119 GRN mutation carriers (88 presymptomatic, ...
Source
#1Rhian S. Convery (UCL Institute of Neurology)H-Index: 2
#2Jieqing Jiao ('KCL': King's College London)H-Index: 5
Last. Jonathan D. Rohrer (UCL Institute of Neurology)H-Index: 50
view all 16 authors...
Mutations in the microtubule associated protein tau ( MAPT ) gene are a common cause of inherited frontotemporal dementia (FTD) and result in the deposition of pathological tau protein in the brain.1 Tau positron emission tomography (PET) may enhance in vivo diagnosis and testing of tau-based therapies in FTD, however, few tau ligands have been validated in FTD. The (18F)AV-1451 ligand was developed to assess in vivo tau accumulation and has consistently been shown to bind to tau in individuals ...
Source
#1Andre Altmann (UCL: University College London)H-Index: 21
#2David M. Cash (UCL: University College London)H-Index: 26
Last. Jonathan D. Rohrer (UCL: University College London)H-Index: 50
view all 35 authors...
Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder characterized by neuronal loss in the frontal and temporal lobes. Despite progress in understanding which genes are associated with the aetiology of FTD (C9orf72, GRN and MAPT), the biological basis of how mutations in these genes lead to cell loss in specific cortical regions remains unclear. In this work we combined gene expression data for 16,912 genes from the Allen Institute for Brain Science atlas with brain maps o...
Source
#1Emma L. van der Ende (EUR: Erasmus University Rotterdam)H-Index: 4
#2Lieke H.H. Meeter (EUR: Erasmus University Rotterdam)H-Index: 8
Last. John C. van Swieten (EUR: Erasmus University Rotterdam)H-Index: 53
view all 43 authors...
Summary Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN, C9orf72, and MAPT. A better understanding of NfL dynamics is essential for upcoming therapeutic trials. We aimed to study longitudinal NfL trajectories in people with presymptomatic and symptomatic genetic frontotemporal dementia. Methods We recruited participants from 14 centres collaborating in the Geneti...
3 CitationsSource
#1Daniel Jimenez (UCL: University College London)
#2Rebecca L. Bond (UCL: University College London)H-Index: 5
Last. Jason D. Warren (UCL: University College London)H-Index: 59
view all 11 authors...
Abnormal reactivity to emotional stimuli is a hallmark of frontotemporal dementia (FTD). In everyday life, we rarely experience intense fear but this can occur in the context of phobias. Some patients with dementia, particularly the behavioural and semantic variants of FTD, experience altered phobic responses. However, these have not been systematically studied. Here we collected caregiver reports about phobic responses following onset of disease in a cohort of patients representing different de...
Source
#1Tara P. Sani (UCL Institute of Neurology)
#2Rebecca L. Bond (UCL Institute of Neurology)H-Index: 5
Last. Jason D. Warren (UCL Institute of Neurology)H-Index: 59
view all 16 authors...
Abstract Sleep disruption is a key clinical issue in the dementias but the sleep phenotypes of these diseases remain poorly characterised. Here we addressed this issue in a proof-of-principle study of 67 patients representing major syndromes of frontotemporal dementia (FTD) and Alzheimer’s disease (AD), in relation to 25 healthy older individuals. We collected reports on clinically-relevant sleep characteristics - time spent overnight in bed, sleep quality, excessive daytime somnolence and disru...
Source
#1Tamara P. TavaresH-Index: 4
Last. Elizabeth FingerH-Index: 25
view all 23 authors...
Objective To characterize the time course of ventricular volume expansion in genetic frontotemporal dementia (FTD) and identify the onset time and rates of ventricular expansion in presymptomatic FTD mutation carriers. Methods Participants included patients with a mutation in MAPT, PGRN, or C9orf72, or first-degree relatives of mutation carriers from the GENFI study with MRI scans at study baseline and at 1 year follow-up. Ventricular volumes were obtained from MRI scans using FreeSurfer, with m...
2 CitationsSource
#1Charles R. Marshall (UCL Institute of Neurology)H-Index: 6
#2Chris J.D. Hardy (UCL Institute of Neurology)H-Index: 6
Last. Jason D. Warren (UCL Institute of Neurology)H-Index: 59
view all 13 authors...
1 CitationsSource
12